APO RESEARCH · REPORT
Live Biotherapeutic Products (LBP) and Microbiome CDMO Service
Selected research
Industry Research
Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Industry Research Report 2026
Market perspective
The global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Live Biotherapeutic Products (LBP) and Microbiome CDMO Service market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Live Biotherapeutic Products (LBP) and Microbiome CDMO Service market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Live Biotherapeutic Products (LBP) and Microbiome CDMO Service market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Live Biotherapeutic Products (LBP) and Microbiome CDMO Service include Lallemand Health Solutions, Wacker Chemie AG, Biose Industrie, List Biological Labs, Inc., NIZO, SGS (Quay Pharmaceuticals), Assembly Biosciences, Inc., Recipharm (Arranta Bio) and Bacthera (Novonesis+Lonza), among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Live Biotherapeutic Products (LBP) and Microbiome CDMO Service.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market by Company
Lallemand Health Solutions
Wacker Chemie AG
Biose Industrie
List Biological Labs, Inc.
NIZO
SGS (Quay Pharmaceuticals)
Assembly Biosciences, Inc.
Recipharm (Arranta Bio)
Bacthera (Novonesis+Lonza)
Smaltis
Lonza
vermicon AG
Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Segment by Type
Solid Dosage Form
Liquid Dosage Form
Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Segment by Application
Digestive System Diseases
Immune System Diseases
Metabolic Diseases
Other
Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Live Biotherapeutic Products (LBP) and Microbiome CDMO Service and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Live Biotherapeutic Products (LBP) and Microbiome CDMO Service.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Live Biotherapeutic Products (LBP) and Microbiome CDMO Service companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Solid Dosage Form
- Liquid Dosage Form
Applications
- Digestive System Diseases
- Immune System Diseases
- Metabolic Diseases
- Other
Companies covered
- Lallemand Health Solutions
- Wacker Chemie AG
- Biose Industrie
- List Biological Labs, Inc.
- NIZO
- SGS (Quay Pharmaceuticals)
- Assembly Biosciences, Inc.
- Recipharm (Arranta Bio)
- Bacthera (Novonesis+Lonza)
- Smaltis
- Lonza
- vermicon AG
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Solid Dosage Form
- 2.2.3 Liquid Dosage Form
- 2.3 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Digestive System Diseases
- 2.3.3 Immune System Diseases
- 2.3.4 Metabolic Diseases
- 2.3.5 Other
- 2.4 Assumptions and Limitations
3 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Breakdown Data by Type
- 3.1 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Historic Market Size by Type (2021-2026)
- 3.2 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Forecasted Market Size by Type (2027-2032)
4 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Breakdown Data by Application
- 4.1 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Historic Market Size by Application (2021-2026)
- 4.2 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Perspective (2021-2032)
- 5.2 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Growth Trends by Region
- 5.2.1 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Historic Market Size by Region (2021-2026)
- 5.2.3 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Forecasted Market Size by Region (2027-2032)
- 5.3 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Dynamics
- 5.3.1 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Industry Trends
- 5.3.2 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Drivers
- 5.3.3 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Challenges
- 5.3.4 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Players by Revenue
- 6.1.1 Global Top Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Players by Revenue (2021-2026)
- 6.1.2 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Market Share by Players (2021-2026)
- 6.2 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Head Office and Area Served
- 6.4 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Players, Product Type & Application
- 6.5 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Manufacturers Established Date
- 6.6 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (2021-2032)
- 7.2 North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (2021-2026)
- 7.4 North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (2021-2032)
- 8.2 Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (2021-2026)
- 8.4 Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (2021-2032)
- 9.2 Asia-Pacific Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (2021-2032)
- 10.2 South America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (2021-2026)
- 10.4 South America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (2021-2032)
- 11.2 Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Lallemand Health Solutions
- 12.1.1 Lallemand Health Solutions Company Information
- 12.1.2 Lallemand Health Solutions Business Overview
- 12.1.3 Lallemand Health Solutions Revenue in Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Business (2021-2026)
- 12.1.4 Lallemand Health Solutions Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio
- 12.1.5 Lallemand Health Solutions Recent Developments
- 12.2 Wacker Chemie AG
- 12.2.1 Wacker Chemie AG Company Information
- 12.2.2 Wacker Chemie AG Business Overview
- 12.2.3 Wacker Chemie AG Revenue in Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Business (2021-2026)
- 12.2.4 Wacker Chemie AG Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio
- 12.2.5 Wacker Chemie AG Recent Developments
- 12.3 Biose Industrie
- 12.3.1 Biose Industrie Company Information
- 12.3.2 Biose Industrie Business Overview
- 12.3.3 Biose Industrie Revenue in Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Business (2021-2026)
- 12.3.4 Biose Industrie Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio
- 12.3.5 Biose Industrie Recent Developments
- 12.4 List Biological Labs, Inc.
- 12.4.1 List Biological Labs, Inc. Company Information
- 12.4.2 List Biological Labs, Inc. Business Overview
- 12.4.3 List Biological Labs, Inc. Revenue in Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Business (2021-2026)
- 12.4.4 List Biological Labs, Inc. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio
- 12.4.5 List Biological Labs, Inc. Recent Developments
- 12.5 NIZO
- 12.5.1 NIZO Company Information
- 12.5.2 NIZO Business Overview
- 12.5.3 NIZO Revenue in Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Business (2021-2026)
- 12.5.4 NIZO Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio
- 12.5.5 NIZO Recent Developments
- 12.6 SGS (Quay Pharmaceuticals)
- 12.6.1 SGS (Quay Pharmaceuticals) Company Information
- 12.6.2 SGS (Quay Pharmaceuticals) Business Overview
- 12.6.3 SGS (Quay Pharmaceuticals) Revenue in Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Business (2021-2026)
- 12.6.4 SGS (Quay Pharmaceuticals) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio
- 12.6.5 SGS (Quay Pharmaceuticals) Recent Developments
- 12.7 Assembly Biosciences, Inc.
- 12.7.1 Assembly Biosciences, Inc. Company Information
- 12.7.2 Assembly Biosciences, Inc. Business Overview
- 12.7.3 Assembly Biosciences, Inc. Revenue in Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Business (2021-2026)
- 12.7.4 Assembly Biosciences, Inc. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio
- 12.7.5 Assembly Biosciences, Inc. Recent Developments
- 12.8 Recipharm (Arranta Bio)
- 12.8.1 Recipharm (Arranta Bio) Company Information
- 12.8.2 Recipharm (Arranta Bio) Business Overview
- 12.8.3 Recipharm (Arranta Bio) Revenue in Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Business (2021-2026)
- 12.8.4 Recipharm (Arranta Bio) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio
- 12.8.5 Recipharm (Arranta Bio) Recent Developments
- 12.9 Bacthera (Novonesis+Lonza)
- 12.9.1 Bacthera (Novonesis+Lonza) Company Information
- 12.9.2 Bacthera (Novonesis+Lonza) Business Overview
- 12.9.3 Bacthera (Novonesis+Lonza) Revenue in Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Business (2021-2026)
- 12.9.4 Bacthera (Novonesis+Lonza) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio
- 12.9.5 Bacthera (Novonesis+Lonza) Recent Developments
- 12.10 Smaltis
- 12.10.1 Smaltis Company Information
- 12.10.2 Smaltis Business Overview
- 12.10.3 Smaltis Revenue in Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Business (2021-2026)
- 12.10.4 Smaltis Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio
- 12.10.5 Smaltis Recent Developments
- 12.11 Lonza
- 12.11.1 Lonza Company Information
- 12.11.2 Lonza Business Overview
- 12.11.3 Lonza Revenue in Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Business (2021-2026)
- 12.11.4 Lonza Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio
- 12.11.5 Lonza Recent Developments
- 12.12 vermicon AG
- 12.12.1 vermicon AG Company Information
- 12.12.2 vermicon AG Business Overview
- 12.12.3 vermicon AG Revenue in Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Business (2021-2026)
- 12.12.4 vermicon AG Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio
- 12.12.5 vermicon AG Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst